Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer

NCT ID: NCT00253643

Last Updated: 2017-04-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

89 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-07-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of fish oil and/or green tea may prevent prostate cancer.

PURPOSE: This randomized clinical trial is studying how well a fish oil and/or green tea supplement works in preventing prostate cancer in patients with prostatic intraepithelial neoplasia or who are at risk for developing prostate cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Determine the cancer preventing effects of fish oil supplementation and green tea extract use on markers of alteration in lipid metabolism in prostate tissue samples.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to age (under 65 vs 65 and over). Patients are randomized to 1 of 4 treatment arms.

* Arm I: Patients receive oral fish oil three times daily and oral green tea extract twice daily.
* Arm II: Patients receive an oil placebo three times daily and oral green tea extract twice daily.
* Arm III: Patients receive oral fish oil three times daily and a placebo twice daily.
* Arm IV: Patients receive an oil placebo three times daily and another placebo twice daily.

Treatment in one of the above-listed arms continues for up to 20 weeks in the absence of disease progression or unacceptable toxicity.

All patients undergo a prostate biopsy on the last day of study treatment.

After completion of study treatment, patients receive a follow-up phone call at/around 30 days later.

PROJECTED ACCRUAL: A total of 144 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Precancerous Condition Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I (FO, GT catechin extract)

Patients receive oral fish oil (FO) 3/day and oral green tea (GT) extract 2/day

Group Type EXPERIMENTAL

green tea catechin extract

Intervention Type DIETARY_SUPPLEMENT

Given orally 2 times/day

fish oil

Intervention Type DIETARY_SUPPLEMENT

Given orally 3 times/day

ArmII (FO placebo, GT catechin extract)

Patients receive a fish oil (FO) placebo 3/day and oral green tea (GT) extract 2/day

Group Type EXPERIMENTAL

green tea catechin extract

Intervention Type DIETARY_SUPPLEMENT

Given orally 2 times/day

placebo

Intervention Type OTHER

Given green tea placebo orally 2 times/day

Arm III (FO, GT placebo)

Patients receive oral fish oil (FO) 3/day and a placebo mimicking green tea (GT) catechins 2/day

Group Type EXPERIMENTAL

fish oil

Intervention Type DIETARY_SUPPLEMENT

Given orally 3 times/day

placebo

Intervention Type OTHER

Given olive oil placebo orally 3 times/day

Arm IV (FO placebo, GT placebo)

Patients receive a fish oil (FO) placebo mimicking fish oil 3/day and another placebo mimicking green tea (GT) catechins 2/day

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

Given olive oil placebo orally 3 times/day

placebo

Intervention Type OTHER

Given green tea placebo orally 2 times/day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

green tea catechin extract

Given orally 2 times/day

Intervention Type DIETARY_SUPPLEMENT

fish oil

Given orally 3 times/day

Intervention Type DIETARY_SUPPLEMENT

placebo

Given olive oil placebo orally 3 times/day

Intervention Type OTHER

placebo

Given green tea placebo orally 2 times/day

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Polyphenon E omega-3 fatty acid, n-3 fatty acid, omega-3 polyunsaturated fatty acid, omega-3 PUFA PLCB, olive oil PLCB

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinician recommends repeat biopsy of the prostate ("Repeat" is defined as any recommended biopsy of the prostate subsequent to an earlier biopsy of the prostate)

Exclusion Criteria

* Definitive invasive prostate cancer on initial biopsy
* Significant active medical illness that in the opinion of the clinician would preclude protocol treatment.
* History of ventricular tachycardia or ventricular fibrillation
* Subject reported use of fish oil (greater than 1 gram per day) or green tea supplement within 30 days before Day 1 of study treatment
* Subject reported use of fish oil ≤ 1 gram per day and unwilling to discontinue use for the duration of the trial
* Use of warfarin or need for therapeutic anticoagulation at time of biopsy or at anytime during the course of the trial.
* Subject reported allergy or sensitivity to fish oil, olive oil or green tea
* Subject reported history of hemophilia, van Willebrands disease or other bleeding disorder, except when the subject is evaluated by a hematologist who determines that fish oil supplementation is not contraindicated.
* Total bilirubin greater than institutional upper limit of normal
* Concurrent high risk study participation
Minimum Eligible Age

21 Years

Maximum Eligible Age

120 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

United States Department of Defense

FED

Sponsor Role collaborator

National Cancer Institute (NCI)

NIH

Sponsor Role collaborator

OHSU Knight Cancer Institute

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jackie Shannon

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jackilen Shannon, PhD

Role: PRINCIPAL_INVESTIGATOR

OHSU Knight Cancer Institute

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kaiser Permanente Center for Health Research

Portland, Oregon, United States

Site Status

OHSU Knight Cancer Institute

Portland, Oregon, United States

Site Status

Veterans Affairs Medical Center - Portland

Portland, Oregon, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Zhang Z, Garzotto M, Beer TM, Thuillier P, Lieberman S, Mori M, Stoller WA, Farris PE, Shannon J. Effects of omega-3 Fatty Acids and Catechins on Fatty Acid Synthase in the Prostate: A Randomized Controlled Trial. Nutr Cancer. 2016 Nov-Dec;68(8):1309-1319. doi: 10.1080/01635581.2016.1224365. Epub 2016 Sep 20.

Reference Type DERIVED
PMID: 27646578 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P30CA069533

Identifier Type: NIH

Identifier Source: secondary_id

View Link

OHSU-CI-CPC-04131-LX

Identifier Type: OTHER

Identifier Source: secondary_id

VAMC-04-0303/ M1016

Identifier Type: OTHER

Identifier Source: secondary_id

DOD-W81XWH-04-1-0296

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

OHSU-1117

Identifier Type: OTHER

Identifier Source: secondary_id

KPNW-NW-05SLIEB-01

Identifier Type: OTHER

Identifier Source: secondary_id

CDR0000443617

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.